| Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. | |
| | |
MedLine Citation:
|
PMID: 21081242 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
There is growing evidence that patients with type 2 diabetes mellitus have increased cancer risk. We examined the association between diabetes, cancer, and cancer-related mortality and hypothesized that insulin sensitizers lower cancer-related mortality. Participants in the Diabetes Cardiovascular Risk and Evaluation: Targets and Essential Data for Commitment of Treatment study, a nationwide cross-sectional and prospective epidemiological study, were recruited from German primary care practices. In the cross-sectional study, subjects with type 2 diabetes mellitus had a higher prevalence of malignancies (66/1308, 5.1%) compared to nondiabetic subjects (185/6211, 3.0%) (odds ratio, 1.64; 95% confidence interval, 1.12-2.41) before and after adjustment for age, sex, hemoglobin A(1c), smoking status, and body mass index. Patients on metformin had a lower prevalence of malignancies, comparable with that among nondiabetic patients, whereas those on any other oral combination treatment had a 2-fold higher risk for malignancies even after adjusting for possible confounders; inclusion of metformin in these regimens decreased the prevalence of malignancies. In the prospective analyses, diabetic patients in general and diabetic patients treated with insulin (either as monotherapy or in combination with other treatments) had a 2- and 4-fold, respectively, higher mortality rate than nondiabetic patients, even after adjustment for potential confounders (incidence of cancer deaths in patients with type 2 diabetes mellitus [2.6%] vs the incidence of cancer deaths in patients without type 2 diabetes mellitus [1.2%]). Our results suggest that diabetes and medications for diabetes, with the exception of the insulin sensitizer metformin, increase cancer risk and mortality. |
| | |
Authors:
|
Dorothee M Baur; Jens Klotsche; Ole-Petter R Hamnvik; Caroline Sievers; Lars Pieper; Hans-Ulrich Wittchen; Günter K Stalla; Roland M Schmid; Stefanos N Kales; Christos S Mantzoros |
Publication Detail:
|
Type: Journal Article Date: 2010-11-16 |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 60 ISSN: 1532-8600 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-19 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: United States |
Other Details:
|
Languages: eng Pagination: 1363-71 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Inc. All rights reserved. |
Affiliation:
|
Harvard School of Public Health, Department of Environmental Health, Environmental and Occupational Medicine and Epidemiology (EOME), Boston, MA, USA; The Cambridge Health Alliance, Harvard Medical School, Employee Health and Industrial Medicine, Cambridge, MA, USA; 2nd Medical Department, Klinkum rechts der Isar, Technical University of Munich, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acute dengue virus myositis: a report of seven patients of varying clinical severity including two c...
Next Document: Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency ...